CDKN2A and melanoma: We posit that, direct or up/down-stream “pharmacologic normalization” of the R87P-p16 mutation, individually and together with BRAF intervention [26], may enable more effective strategies to delay or even prevent FM, including the occurrence of melanoma in individuals who are otherwise at risk.